Skip to main content
Erschienen in: hautnah dermatologie 3/2020

27.05.2020 | Psoriasis vulgaris | Zertifizierte Fortbildung

Internationale Empfehlungen

Therapie der Psoriasisarthritis

verfasst von: Dr. med. Frank Behrens, Dr. med. Michaela Köhm

Erschienen in: hautnah dermatologie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Die Psoriasisarthritis ist eine heterogene Erkrankung, die neben der Beteiligung von Haut und Gelenken auch enthesiale, axiale und extramuskuloskeletale Manifestationsformen sowie Assoziationen mit weiteren Erkrankungen aufweisen kann. Die individualisierte Auswahl einer effektiven Therapie sollte daher stets patientenorientiert und unter Berücksichtigung der unterschiedlichen Manifestationen getroffen werden. …
Literatur
1.
Zurück zum Zitat Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160: 1040-7 Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160: 1040-7
2.
Zurück zum Zitat Helliwell PS etl al. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64: ii3-8 Helliwell PS etl al. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64: ii3-8
3.
Zurück zum Zitat Coates LC et al. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010; 62: 965-9 Coates LC et al. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010; 62: 965-9
4.
Zurück zum Zitat Coates LC et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; 386: 2489-98 Coates LC et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; 386: 2489-98
5.
Zurück zum Zitat Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Therapieleitlinie der Psoriasis vulgaris. 2011; www.AWMF.org. Zugegriffen: 2020 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Therapieleitlinie der Psoriasis vulgaris. 2011; www.AWMF.org. Zugegriffen: 2020
6.
Zurück zum Zitat Nast A et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1. J Dtsch Dermatol Ges. 2018; 16: 645-69 Nast A et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1. J Dtsch Dermatol Ges. 2018; 16: 645-69
7.
Zurück zum Zitat Gossec L et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75: 499-510 Gossec L et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75: 499-510
8.
Zurück zum Zitat Coates LC et al. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016; 174: 1174-8 Coates LC et al. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016; 174: 1174-8
9.
Zurück zum Zitat Behrens F et al. Psoriatic arthritis: Overview of drug therapy options and administration characteristics. Hautarzt. 2017; 68: 153-69 Behrens F et al. Psoriatic arthritis: Overview of drug therapy options and administration characteristics. Hautarzt. 2017; 68: 153-69
10.
Zurück zum Zitat Eder L et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford), 2010; 49: 1367-73 Eder L et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford), 2010; 49: 1367-73
11.
Zurück zum Zitat Kingsley GH et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012; 51: 1368-77 Kingsley GH et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012; 51: 1368-77
12.
Zurück zum Zitat Baranauskaite A et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012; 71: 541-8 Baranauskaite A et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012; 71: 541-8
13.
Zurück zum Zitat Behrens F et al. Does concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? Data from a large observational study. J Rheumatol. 2016; 43: 632-9 Behrens F et al. Does concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? Data from a large observational study. J Rheumatol. 2016; 43: 632-9
14.
Zurück zum Zitat Mease PJ et al. Etanercept and Methotrexate as Monotherapy or in combination for Psoriatic arthritis: primary results from a randomized, controlled phase 3 trial. Arthritis Rheumatol. 2019; 71: 1112-24. Mease PJ et al. Etanercept and Methotrexate as Monotherapy or in combination for Psoriatic arthritis: primary results from a randomized, controlled phase 3 trial. Arthritis Rheumatol. 2019; 71: 1112-24.
15.
Zurück zum Zitat Fagerli KM et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014; 73: 132-7 Fagerli KM et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014; 73: 132-7
16.
Zurück zum Zitat Behrens F et al. Update 2011: leflunomide in rheumatoid arthritis -strengths and weaknesses. Curr Opin Rheumatol. 2011; 23: 282-7 Behrens F et al. Update 2011: leflunomide in rheumatoid arthritis -strengths and weaknesses. Curr Opin Rheumatol. 2011; 23: 282-7
17.
Zurück zum Zitat Kaltwasser et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, doubleblind, randomized, placebocontrolled clinical trial. Arthritis Rheum. 2004; 50: 1939-50 Kaltwasser et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, doubleblind, randomized, placebocontrolled clinical trial. Arthritis Rheum. 2004; 50: 1939-50
18.
Zurück zum Zitat Nash P et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006; 212: 238-49 Nash P et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006; 212: 238-49
19.
Zurück zum Zitat Ho VC et al. Intermittent short courses of cyclosporin for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999; 141: 283-91 Ho VC et al. Intermittent short courses of cyclosporin for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999; 141: 283-91
20.
Zurück zum Zitat Acosta Felquer ML et al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41: 2277-85 Acosta Felquer ML et al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41: 2277-85
21.
Zurück zum Zitat Clegg DO et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum. 1996; 39: 2013-20 Clegg DO et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum. 1996; 39: 2013-20
22.
Zurück zum Zitat Cutolo M et al .A phase III, randomized, controlled trial of Apremilast in patients with Psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016; 43: 1724-34 Cutolo M et al .A phase III, randomized, controlled trial of Apremilast in patients with Psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016; 43: 1724-34
23.
Zurück zum Zitat Gladman D et al. Tofacitinib for Psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017; 377: 1525-36 Gladman D et al. Tofacitinib for Psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017; 377: 1525-36
24.
Zurück zum Zitat Yoo DH et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72: 1613-20 Yoo DH et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72: 1613-20
25.
Zurück zum Zitat Zweegers J et al. Comparison of the one and 5 years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: results from the prospective bioCAPTURE registry. Br J Dermatol. 2017; 176: 1001-9 Zweegers J et al. Comparison of the one and 5 years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: results from the prospective bioCAPTURE registry. Br J Dermatol. 2017; 176: 1001-9
26.
Zurück zum Zitat Leonardi CL Y et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665-74 Leonardi CL Y et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665-74
27.
Zurück zum Zitat Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo- controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-84 Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo- controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-84
28.
Zurück zum Zitat McInnes IB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382: 780-9 McInnes IB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382: 780-9
29.
Zurück zum Zitat Ritchlin C et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6 month and 1 year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73: 990-9 Ritchlin C et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6 month and 1 year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73: 990-9
30.
Zurück zum Zitat Araujo EG et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019; 48: 632-7 Araujo EG et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019; 48: 632-7
31.
Zurück zum Zitat Mease PJ et al. Secukinumab inhibition of Interleukin-17A in patients with Psoriatic arthritis. N Engl J Med. 2015; 373: 1329-39 Mease PJ et al. Secukinumab inhibition of Interleukin-17A in patients with Psoriatic arthritis. N Engl J Med. 2015; 373: 1329-39
32.
Zurück zum Zitat Langley RG et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014; 371: 326-38 Langley RG et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014; 371: 326-38
33.
Zurück zum Zitat Krueger JG et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130: 145-54 Krueger JG et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130: 145-54
34.
Zurück zum Zitat Griffiths CE et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER 2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386: 541-51 Griffiths CE et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER 2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386: 541-51
35.
Zurück zum Zitat Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015; 27: 127-33 Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015; 27: 127-33
36.
Zurück zum Zitat Mease PJ et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370: 2295-306 Mease PJ et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370: 2295-306
37.
Zurück zum Zitat Papp K et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71: 1183-90.e3 Papp K et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71: 1183-90.e3
38.
Zurück zum Zitat Papp K CE et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2015; 72: 436-9e1 Papp K CE et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2015; 72: 436-9e1
39.
Zurück zum Zitat Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017; 76: 405-17 Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017; 76: 405-17
40.
Zurück zum Zitat Coates LC et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68: 1060-71 Coates LC et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68: 1060-71
Metadaten
Titel
Internationale Empfehlungen
Therapie der Psoriasisarthritis
verfasst von
Dr. med. Frank Behrens
Dr. med. Michaela Köhm
Publikationsdatum
27.05.2020
Verlag
Springer Medizin
Erschienen in
hautnah dermatologie / Ausgabe 3/2020
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-020-4032-2

Weitere Artikel der Ausgabe 3/2020

hautnah dermatologie 3/2020 Zur Ausgabe